Health & Fitness
Health and Fitness
Health and Fitness 
Mon, May 16, 2011
CEO of ARCA biopharma to Present Gencaro Development Programs at the European Society of Cardiologya?s Heart Failure Congress 2
BROOMFIELD, Colo.--([ BUSINESS WIRE ])--ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company developing genetically-targeted therapies for cardiovascular diseases, today announced that Dr. Michael Bristow, President and Chief Executive Officer, has been selected to present in the "Update from Industry" session at the Heart Failure Congress 2011, organized by the Heart Failure Association of the European Society of Cardiology (HFA of the ESC), being held in Gothenburg, Sweden, May 21 a" 24, 2011. Dr. Bristowa™s presentation, on Sunday, May 22, 2011, is entitled aPharmacogenetic Targeting of Bucindolol in Heart Failure and Atrial Fibrillation.a
"Pharmacogenetic Targeting of Bucindolol in Heart Failure and Atrial Fibrillation."
More information about the conference is available at: [ http://www.escardio.org/congresses/HF2011/Pages/welcome.aspx ].
About ARCA biopharma
ARCA biopharma is dedicated to developing genetically-targeted therapies for cardiovascular diseases. The Company's lead product candidate, GencaroTM (bucindolol hydrochloride), is an investigational, pharmacologically unique beta-blocker being developed for heart failure and atrial fibrillation. ARCA has identified common genetic variations that it believes predict individual patient response to Gencaro, giving it the potential to be the first genetically-targeted heart failure and/or atrial fibrillation prevention treatment. ARCA is collaborating with Laboratory Corporation of America on the companion genetic test for Gencaro.
For more information please visit [ www.arcabiopharma.com ].
Safe Harbor Statement
This press release and the anticipated presentation contain "forward-looking statements" for purposes of the safe harbor provided by the Private Securities Litigation Reform Act of 1995. These statements include, but are not limited to, statements regarding the ability of genetic variations to predict individual patient response to Gencaro, and the potential for Gencaro to be the first genetically-targeted heart failure and/or atrial fibrillation prevention treatment. Such statements are based on management's current expectations and involve risks and uncertainties. Actual results and performance could differ materially from those projected in the forward-looking statements as a result of many factors, including, without limitation, the risks and uncertainties associated with: the Company's financial resources and whether they will be sufficient to meet the Company's business objectives and operational requirements; the protection and market exclusivity provided by the Companya™s intellectual property; risks related to the drug discovery and the regulatory approval process; and, the impact of competitive products and technological changes. These and other factors are identified and described in more detail in ARCAa™s filings with the SEC, including without limitation the Companya™s annual report on Form 10-K for the year ended December 31, 2010 and subsequent filings. The Company disclaims any intent or obligation to update these forward-looking statements.